# Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer

> **NCT05310344** · PHASE2 · UNKNOWN · sponsor: **Lei Li** · enrollment: 50 (estimated)

## Conditions studied

- Ovarian Carcinoma
- Platinum-resistant Ovarian Cancer
- Recurrent Ovarian Carcinoma
- Albumin-bound Paclitaxel
- Bevacizumab
- Survival Outcomes
- Adverse Events

## Interventions

- **COMBINATION_PRODUCT:** Albumin-bound paclitaxel and bevacizumab

## Key facts

- **NCT ID:** NCT05310344
- **Lead sponsor:** Lei Li
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-27
- **Primary completion:** 2023-03-27
- **Final completion:** 2024-03-27
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05310344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05310344, "Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05310344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*